hotspot -WSS

hotspot

author：focus 2025-08-11 07:59:01 - browse：716

Pfizer is this year’s anti-Eli Lilly. If David Ricks is the best biopharma CEO of 2023, then Pfizer CEO Albert Bourlais, unfortunately, the worst.

My annual Worst Biopharma CEO list is typically populated with blockheads and scoundrels. That’s not why Bourla is here. The reason is accountability. Strategic missteps, financial miscalculations, and scientific setbacks have plunged Pfizer into a deep crisis. Bourla is the man at the top, so the responsibility lies with him.

Pfizer shares have fallen 50% this year to their lowest level in more than a decade, erasing nearly $140 billion in market value. In 2022, the company delivered $100 billion in revenue, boosted by a widely used Covid vaccine and Covid treatment. This year, Covid product sales evaporated — and will fall further next year — leaving a vacuum Pfizer is struggling to fill with aging medicines nearing the end of their patent lives, and newer drugs and vaccines that have not performed as expected.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： Kellogg’s is going to war over Mexico’s nutrition label rules

WSS

Hospital at home shows how to bring innovation to health care

Vir antibody drug aimed at influenza A fails in clinical trial

Tocagen's brain cancer gene therapy trial continues. Investors worry

CDC says it’s too soon to assess risk posed by Covid subvariant

FDA greenlights medical device to combat bladder issues

7 more heat

knowledge

hotspot

focus

Tori Bowie and the unacceptable rates of Black maternal death

FDA greenlights medical device to combat bladder issues

Cancer drug shortages should be causing more outrage

Mass General totes up its waste in a move to tackle climate change

Heart attack and stroke risk calculators need revising

7 more heat

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

DeSantis talks Trump, trans issues and 'what wokeness is'

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Vir antibody drug aimed at influenza A fails in clinical trial

leisure time

PBMs are inflating the cost of generic drugs. They must be reined in

Health officials lay out plans to cope with respiratory virus season

Stanford president faces new allegations over 1999 paper

CDC says it’s too soon to assess risk posed by Covid subvariant

How the first Native Hawaiian psychiatrist helped diversify medicine

Senate committee advances SCOTUS ethics bill after alleged justice misconduct

entertainment

Wikipedia

explore

explore